| 查看: 1790 | 回复: 101 | |||
[交流]
【转自药渡网】Teva 报告了乐观哮喘临床3期评估结果
|
|||
|
Teva 对临床3期评估了对于哮喘患者干粉吸入器 (MDPIs)吸入Fluticasone Propionate /Salmeterol和多剂量Fluticasone Propionate 的实验效果，实验数据很好。研究表明通过使用干粉吸入器 (MDPI)，低剂量与安慰剂相比具有更大的效能，结果展示 Teva 扩大呼吸的研发能力和支持其核心，呼吸驱动MDPI平台的发展。最初的结果显示fluticasone propionate/salmeterol MDPI的不良事件可以和fluticasone propionate治疗和安慰剂媲美。 相关阅读： Teva Reports Positive Top-Line Results from Phase III Trials Evaluating Fluticasone Propionate/Salmeterol and Fluticasone Propionate Multidose Dry Powder Inhalers (MDPIs) in Patients with Asthma Studies demonstrate greater efficacy with lower doses delivered via multidose dry-powder inhaler (MDPI) compared to placebo Results showcase Teva’s expanding respiratory R&D capabilities and support advancement of core, breath-actuated MDPI platform Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced positive top-line results from three Phase III clinical studies designed to evaluate the efficacy and safety of fluticasone propionate/salmeterol, a combination inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) delivered via a multidose dry powder inhaler (MDPI) and fluticasone propionate, an ICS monotherapy delivered via a MDPI in adolescent and adult patients with asthma. Top-line data showed that the studies met their primary endpoints. Importantly, the studies also showed similar overall safety profiles as compared to therapies in the corresponding drug classes. “These data support Teva’s commitment to further optimize the treatment of respiratory disease through the development of devices and therapies that help address the needs of patients and physicians,” said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. “With this dual development program we have demonstrated clinically significant levels of effectiveness, by delivering combination and monotherapy at lower doses utilizing our core, breath-actuated, MDPI platform.” Fluticasone propionate/salmeterol MDPI demonstrated, in the double-blind studies, clinically relevant and greater benefit at all doses (50/12.5, 100/12.5, and 200/12.5 mcg BID nominal delivered doses) versus placebo and versus respective monotherapy (fluticasone propionate) in the improvement of lung function as measured by the change from baseline in trough Forced Expiratory Volume in one second (FEV1) at the 12-week trial period and standardized baseline-adjusted area under the effect curve FEV1 from time 0 to 12 hours post dose at Week 12. This initial set of results shows the adverse event profile of fluticasone propionate/salmeterol MDPI was comparable to fluticasone propionate monotherapy and placebo. Fluticasone propionate MDPI also demonstrated clinically relevant and greater benefit at all doses (50, 100, and 200 mcg BID nominal delivered doses) versus placebo in the improvement of lung function, in the double-blind studies. The initial set of results shows the adverse event profile of fluticasone propionate MDPI was comparable to placebo. The majority of adverse events were mild to moderate in severity. There were no drug-related deaths across any of the trials. Further analyses of additional efficacy and safety data are ongoing. Full results will be submitted for presentation at future scientific meetings and for publication in peer reviewed journals. “We have made significant progress in furthering our respiratory pipeline with a focus on a complete asthma management system utilizing our breath-actuated MDPI platform,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva. “We have successfully developed and launched products that utilize our breath-actuated MDPI platform in select markets around the world. These data support the broadening of our portfolio in using this technology to develop and deliver additional respiratory therapeutic options.” Regulatory submissions for both fluticasone propionate/salmeterol MDPI and fluticasone propionate MDPI in the U.S. are planned for 2016. |
回复此楼» 猜你喜欢
一志愿华中科技大学071000，求调剂
已经有3人回复
-
279分求调剂 一志愿211
已经有14人回复
-
332求调剂
已经有3人回复
-
0856材料专硕353求调剂
已经有3人回复
-
材料学学硕080502 337求调剂-一志愿华中科技大学
已经有5人回复
-
085601调剂 358分
已经有4人回复
-
0856 271求调剂
已经有3人回复
-
能源材料化学课题组招收硕士研究生8-10名
已经有15人回复
-
一志愿西安交通大学材料工程专业 282分求调剂
已经有9人回复
-
一志愿重庆大学085700资源与环境总分308求调剂
已经有6人回复
» 抢金币啦！回帖就可以得到:
-
人生已过半程，不惑之年渐近，回望来时路，满心皆是感恩。
+5/1795
-
青岛高校2026招生硕士研究生
+5/775
-
农业信息工程技术（专硕）招收调剂 沈阳农业大学
+1/184
-
浙江农林大学招收调剂
+1/79
-
愿遇见你，遇见不止擦肩而过的缘分
+1/74
-
招收2026年材料与化工专硕调剂，全国重点实验室，过国家线即可调剂，名额充足
+2/48
-
湘潭大学“过程强化与绿色化工”创新团队补招2026年秋入学博士生
+1/35
-
研究生 调剂 看过来- 机械、控制工程、力学类（流体力学、一般力学等） 211 双一流
+1/29
-
同济大学环境学院 肖倩特聘研究员课题组 招聘硕士/博士（长期有效）
+1/25
-
下周见一个合作者，应该问些什么
+1/25
-
南京林业大学-国家级青年人才团队 招2026级博士、硕士（合成化学、植物化学方向）
+1/22
-
招聘科研助理——储能方向（储能、流体传热、CFD模拟）
+1/16
-
湖南大学微生物结构与功能实验室2026年计划招收博士研究生
+1/15
-
宁波东方理工大学余鹏课题组2026年上海交大联培博士生、博士后、科研助理招聘
+1/14
-
南昌一本市政工程接受调剂
+1/13
-
【2026博士招生/博后招聘】北京航空航天大学潘彪课题组——AI芯片设计方向
+1/11
-
新加坡国立大学药学系化学生物学课题组招PhD
+1/11
-
青岛科技大学化工学院院士团队2026年拟招收全日制博士研究生1名
+1/8
-
中科院上海微系统所材料生长理论与仿真课题组-博士后招聘（材料计算与AI4S）
+1/2
-
【2026年春季补录】厦门大学田中群院士/易骏教授纳米光子学团队招收2026年入学博士生
+1/1
★
药渡(金币+1): 谢谢参与
药渡(金币+1): 谢谢参与
|
本帖内容被屏蔽 |
14楼2015-11-20 16:01:12
简单回复
sxln2楼
2015-11-20 15:48
回复
药渡(金币+1): 谢谢参与
laom20133楼
2015-11-20 15:50
回复
药渡(金币+1): 谢谢参与
2015-11-20 15:50
回复
药渡(金币+1): 谢谢参与
2015-11-20 15:50
回复
药渡(金币+1): 谢谢参与
。 发自小木虫Android客户端
天涯20126楼
2015-11-20 15:51
回复
药渡(金币+1): 谢谢参与
skyish7楼
2015-11-20 15:52
回复
药渡(金币+1): 谢谢参与
2015-11-20 15:54
回复
药渡(金币+1): 谢谢参与
dmbb9楼
2015-11-20 15:57
回复
药渡(金币+1): 谢谢参与
江南的竹10楼
2015-11-20 15:58
回复
药渡(金币+1): 谢谢参与
。 [ 发自小木虫客户端 ]
chenchenyf11楼
2015-11-20 15:59
回复
药渡(金币+1): 谢谢参与
xiejiaf12楼
2015-11-20 16:00
回复
药渡(金币+1): 谢谢参与
feiyief13楼
2015-11-20 16:01
回复
药渡(金币+1): 谢谢参与
mhycpxir15楼
2015-11-20 16:01
回复
药渡(金币+1): 谢谢参与
irshvj16楼
2015-11-20 16:02
回复
药渡(金币+1): 谢谢参与
kolimm17楼
2015-11-20 16:02
回复
药渡(金币+1): 谢谢参与
祝福
am435918楼
2015-11-20 16:02
回复
药渡(金币+1): 谢谢参与
wblxcs19楼
2015-11-20 16:02
回复
药渡(金币+1): 谢谢参与
祝福
wnotffisg20楼
2015-11-20 16:03
回复
药渡(金币+1): 谢谢参与
祝福
ahsjlyu21楼
2015-11-20 16:03
回复
药渡(金币+1): 谢谢参与
.
keoxri22楼
2015-11-20 16:03
回复
药渡(金币+1): 谢谢参与
vrxcyvkss23楼
2015-11-20 16:03
回复
药渡(金币+1): 谢谢参与
,
ooxmfc24楼
2015-11-20 16:04
回复
药渡(金币+1): 谢谢参与
ucmxjl25楼
2015-11-20 16:04
回复
药渡(金币+1): 谢谢参与
,
bincmq26楼
2015-11-20 16:04
回复
药渡(金币+1): 谢谢参与
祝福
fqmkia27楼
2015-11-20 16:04
回复
药渡(金币+1): 谢谢参与
wxubpn28楼
2015-11-20 16:05
回复
药渡(金币+1): 谢谢参与
祝福
iygbojqj29楼
2015-11-20 16:05
回复
药渡(金币+1): 谢谢参与
sjtdeud30楼
2015-11-20 16:05
回复
药渡(金币+1): 谢谢参与
shsvoy31楼
2015-11-20 16:05
回复
药渡(金币+1): 谢谢参与
cmyfna32楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
sgadsdkc33楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
,
quainyni34楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
wbwwrs35楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
祝福
yuduoj36楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
支持
ofresq37楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
.
tanmingp38楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
qdjoupudwqx39楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
,
qyoycw40楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
fangfengw41楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
祝福
virologik42楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
liufeic43楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
xiachaz44楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
hodydo45楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
zhangfangp46楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
hudouz47楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
祝福
ffwmeg48楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
.
yushat49楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
qiyingy50楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
支持
